Clinical Trial Update: Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants [Phase 3]

View source ↗

Summary

Phase 3 trial assessing olanzapine for nausea and vomiting prophylaxis in recipients of hematopoietic stem cell transplants has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED | Results posted: 2023-05-09